The daughter - in-law
28.05.2005, 07:45
The universal preparation against a HIV is created
The version for a press or seal
To send the link to the friend
On February, 10th 2006. The laboratory researches spent at University Vanderbilta (USA) have shown efficiency of essentially new preparation against a HIV.
The substance which has received name CSA-54, concerns to family so-called tserageninov. TSerageniny for the first time have been synthesized by the doctor Floor Savidzhem from Young's University Briema, and are made by company Ceragenix Pharmaceuticals.
CSA-54 suppresses a HIV-becoming infected human CD4 + the T-lymphocytes, being a primary target of a virus. The mechanism of action of substance essentially differs from action of modern preparations against a HIV. Due to an electrostatic attraction there is linkage CSA-54 to negatively charged or loaded cellular membranes of a HIV, and also some other viruses, mushrooms and bacteria. As a result of it or this linkage of a virus with cells of the person is blocked.
' We have received preliminary, but very encouraging results ', - the author of research Derja Unutmats has informed. - ' that the substance acting on a membrane of a virus, apparently will appear effective against all strains of a virus is especially important, irrespective of mutations as the virus membrane remains not changed '.
Researches in vitro have shown also, that CSA-54 is not toxic or toxiferous in relation to epithelial cells of the person in doses, sufficient for destruction of a virus.
The majority of modern preparations for struggle against a HIV act on a virus in later stage - after a becoming infected of a cell. There is only one preparation which prevents penetration of a virus into cells of immune system of the person - Fuzeon. However Fuzeon, cooperating with koretseptorami the HIV, is not effective against all strains of a virus.
Experts consider or count the results received by the American scientists, encouraging enough, however mark or celebrate, that only clinical researches are capable to confirm efficiency of a new agent.
The version for a press or seal
To send the link to the friend
On February, 10th 2006. The laboratory researches spent at University Vanderbilta (USA) have shown efficiency of essentially new preparation against a HIV.
The substance which has received name CSA-54, concerns to family so-called tserageninov. TSerageniny for the first time have been synthesized by the doctor Floor Savidzhem from Young's University Briema, and are made by company Ceragenix Pharmaceuticals.
CSA-54 suppresses a HIV-becoming infected human CD4 + the T-lymphocytes, being a primary target of a virus. The mechanism of action of substance essentially differs from action of modern preparations against a HIV. Due to an electrostatic attraction there is linkage CSA-54 to negatively charged or loaded cellular membranes of a HIV, and also some other viruses, mushrooms and bacteria. As a result of it or this linkage of a virus with cells of the person is blocked.
' We have received preliminary, but very encouraging results ', - the author of research Derja Unutmats has informed. - ' that the substance acting on a membrane of a virus, apparently will appear effective against all strains of a virus is especially important, irrespective of mutations as the virus membrane remains not changed '.
Researches in vitro have shown also, that CSA-54 is not toxic or toxiferous in relation to epithelial cells of the person in doses, sufficient for destruction of a virus.
The majority of modern preparations for struggle against a HIV act on a virus in later stage - after a becoming infected of a cell. There is only one preparation which prevents penetration of a virus into cells of immune system of the person - Fuzeon. However Fuzeon, cooperating with koretseptorami the HIV, is not effective against all strains of a virus.
Experts consider or count the results received by the American scientists, encouraging enough, however mark or celebrate, that only clinical researches are capable to confirm efficiency of a new agent.